ES2475492B1 - Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro - Google Patents

Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro Download PDF

Info

Publication number
ES2475492B1
ES2475492B1 ES201430343A ES201430343A ES2475492B1 ES 2475492 B1 ES2475492 B1 ES 2475492B1 ES 201430343 A ES201430343 A ES 201430343A ES 201430343 A ES201430343 A ES 201430343A ES 2475492 B1 ES2475492 B1 ES 2475492B1
Authority
ES
Spain
Prior art keywords
composition
vitro assays
abnormal
coagulation control
control plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201430343A
Other languages
English (en)
Other versions
ES2475492A1 (es
Inventor
José SEGUI BORRELL
Daniel Martorell Pena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols SA
Original Assignee
Grifols Worldwide Operations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201430343A priority Critical patent/ES2475492B1/es
Application filed by Grifols Worldwide Operations Ltd filed Critical Grifols Worldwide Operations Ltd
Publication of ES2475492A1 publication Critical patent/ES2475492A1/es
Application granted granted Critical
Publication of ES2475492B1 publication Critical patent/ES2475492B1/es
Priority to CA2883260A priority patent/CA2883260C/en
Priority to CL2015000469A priority patent/CL2015000469A1/es
Priority to EP15382091.5A priority patent/EP2919014B1/en
Priority to ES15382091.5T priority patent/ES2639445T3/es
Priority to CN201510101355.4A priority patent/CN104914256B/zh
Priority to AU2015201260A priority patent/AU2015201260B2/en
Priority to JP2015047974A priority patent/JP6215245B2/ja
Priority to US14/656,362 priority patent/US9482679B2/en
Priority to MX2015003192A priority patent/MX362870B/es
Priority to BR102015005628A priority patent/BR102015005628A8/pt
Priority to ARP150100765A priority patent/AR099753A1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro.#La presente invención se refiere al sector del análisis clínico de la sangre y, más en particular, se refiere a una composición que comprende plasma humano, solución isotónica tamponada y ácido ferúlico para utilizar en el control anormal de la coagulación en ensayos de hemostasia, coagulación y fibrinolisis. Además, la presente invención se refiere a la utilización de ácido ferúlico en la preparación de un control anormal de plasma en ensayos de hemostasia.

Description



imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)



  1. imagen1
    imagen2
ES201430343A 2014-03-13 2014-03-13 Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro Expired - Fee Related ES2475492B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES201430343A ES2475492B1 (es) 2014-03-13 2014-03-13 Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro
CA2883260A CA2883260C (en) 2014-03-13 2015-02-25 Composition for use as an abnormal coagulation control plasma in in vitro assays
CL2015000469A CL2015000469A1 (es) 2014-03-13 2015-02-26 Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro
EP15382091.5A EP2919014B1 (en) 2014-03-13 2015-03-03 Composition for use as an abnormal coagulation control plasma in in vitro assays
ES15382091.5T ES2639445T3 (es) 2014-03-13 2015-03-03 Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro
CN201510101355.4A CN104914256B (zh) 2014-03-13 2015-03-06 用作体外试验中异常凝血对照血浆的组合物
AU2015201260A AU2015201260B2 (en) 2014-03-13 2015-03-11 Composition for use as an abnormal coagulation control plasma in in vitro assays
JP2015047974A JP6215245B2 (ja) 2014-03-13 2015-03-11 インビトロアッセイにおいて凝固異常コントロール血漿として用いるための組成物
MX2015003192A MX362870B (es) 2014-03-13 2015-03-12 Composición para su utilización como plasma de control anormal de la coagulación de ensayos in vitro.
US14/656,362 US9482679B2 (en) 2014-03-13 2015-03-12 Composition for use as an abnormal coagulation control plasma in in vitro assays
BR102015005628A BR102015005628A8 (pt) 2014-03-13 2015-03-13 Composição, e, uso de ácido ferúlico
ARP150100765A AR099753A1 (es) 2014-03-13 2015-03-13 Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430343A ES2475492B1 (es) 2014-03-13 2014-03-13 Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro

Publications (2)

Publication Number Publication Date
ES2475492A1 ES2475492A1 (es) 2014-07-10
ES2475492B1 true ES2475492B1 (es) 2015-01-15

Family

ID=51063211

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201430343A Expired - Fee Related ES2475492B1 (es) 2014-03-13 2014-03-13 Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro
ES15382091.5T Active ES2639445T3 (es) 2014-03-13 2015-03-03 Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15382091.5T Active ES2639445T3 (es) 2014-03-13 2015-03-03 Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro

Country Status (11)

Country Link
US (1) US9482679B2 (es)
EP (1) EP2919014B1 (es)
JP (1) JP6215245B2 (es)
CN (1) CN104914256B (es)
AR (1) AR099753A1 (es)
AU (1) AU2015201260B2 (es)
BR (1) BR102015005628A8 (es)
CA (1) CA2883260C (es)
CL (1) CL2015000469A1 (es)
ES (2) ES2475492B1 (es)
MX (1) MX362870B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108169467B (zh) * 2017-11-27 2019-09-20 中国科学院苏州生物医学工程技术研究所 一种血栓弹力图仪质控品及其制备方法和应用
CN109239373A (zh) * 2018-08-15 2019-01-18 迪瑞医疗科技股份有限公司 一种组织因子酯化物试剂及其制备方法与应用
CN110346582B (zh) * 2019-07-15 2022-10-25 三诺生物传感股份有限公司 一种凝血复合质控品及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705395A (en) * 1994-11-14 1998-01-06 The Scripps Research Institute Method for diagnosis of thrombotic disorders
US6194394B1 (en) * 1998-07-01 2001-02-27 Sigma-Aldrich Co. Coagulation controls for prothrombin time (PT) and activated partial thromboplastin time (APTT) assays
WO2001007921A2 (en) * 1999-07-23 2001-02-01 Medical Analysis Systems, Inc. Stabilized coagulation control reagent
CN103626653B (zh) * 2013-08-14 2015-06-24 河南大学 冬凌草促凝血有效成分及其制备方法和应用

Also Published As

Publication number Publication date
US9482679B2 (en) 2016-11-01
BR102015005628A2 (pt) 2016-04-26
AU2015201260A1 (en) 2015-10-01
EP2919014A1 (en) 2015-09-16
AR099753A1 (es) 2016-08-17
EP2919014B1 (en) 2017-08-16
MX2015003192A (es) 2015-10-29
CL2015000469A1 (es) 2015-10-02
BR102015005628A8 (pt) 2022-07-05
MX362870B (es) 2019-02-20
JP2015175850A (ja) 2015-10-05
CN104914256B (zh) 2018-04-03
ES2475492A1 (es) 2014-07-10
JP6215245B2 (ja) 2017-10-18
US20150260740A1 (en) 2015-09-17
AU2015201260B2 (en) 2018-05-10
CA2883260C (en) 2019-02-19
ES2639445T3 (es) 2017-10-26
CA2883260A1 (en) 2015-09-13
CN104914256A (zh) 2015-09-16

Similar Documents

Publication Publication Date Title
GT201500051A (es) Inhibidores de glucosilceramida sintasa
CO7240369A2 (es) Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
PE20210650A1 (es) Terapia basada en anticuerpos de amiloidosis por transtiretina (ttr) y anticuerpos derivados de humanos de la misma
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
GT201300215A (es) Inhibidores de glucosilceramida sintasa
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
MX350588B (es) Composiciones de alcanos semifluorados.
MX360564B (es) Análisis de coagulación de bajo volumen.
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
BR112017018522A2 (pt) composições e métodos para diagnóstico e tratamento do câncer
AR090307A1 (es) Polimeros cationicos a base de glucogeno
UY34243A (es) Marcadores y metodos para evaluación del riesgo de enfermedades cardiovasculares
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
ES2475492B1 (es) Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
CR20130106A (es) Nuevos moduladores de trpv3
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
CO6990738A2 (es) Agentes de reversion anticoagulante
ECSP13012603A (es) Nueva formulacion del cetp(1)
BR112013031431A2 (pt) método para o diagnóstico da doença de gaucher
BR112015027249A2 (pt) método de diagnóstico de câncer
CL2017001383A1 (es) Proceso para la fabricación de anhídrido carboxílico
BR112015017432A2 (pt) métodos para o tratamento de indicações cardiovasculares
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales
AU2015244572A1 (en) Multipurpose medical image indicator and method for manufacturing same

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2475492

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150115

PC2A Transfer of patent

Owner name: GRIFOLS, S.A.

Effective date: 20150331

FD2A Announcement of lapse in spain

Effective date: 20211001